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Considering the inherent risks related to neurosurgi-cal procedures, such as infections and hemorrhag-es, there is an obvious demand for less invasive 
alternative procedures. Following extensive preclinical 
investigations,4–8,10,11,13,15,24,25,31,32 a clinically relevant pro-
totype of a tcMRgFUS device for thermal ablation was 
developed.9,12,14 Because of its noninvasiveness, focused 
ultrasound technology eliminates the risk of infection, re-
duces the risk of bleeding, and limits collateral damage to 
nontargeted tissue. Magnetic resonance imaging allows 
precise intraprocedural localization of the ablation target, 
definition and verification of safety margins for the ultra-
sound treatment, real-time monitoring of thermal abla-
tion dynamics, and intra- and posttreatment assessment 
of intervention results.2,3,21 The tcMRgFUS technique 
involves the transformation of sonic into thermal energy 
and the production of a thermolesion. The possibility of 
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Object. Recent technological developments open the field of therapeutic application of focused ultrasound to 
the brain through the intact cranium. The goal of this study was to apply the new transcranial magnetic resonance 
imaging–guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies 
(CLTs) as a treatment for chronic neuropathic pain.
Methods. In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was pro-
posed. In 11 patients, precisely localized thermal ablations of 3–4 mm in diameter were produced in the posterior part 
of the central lateral thalamic nucleus at peak temperatures between 51°C and 64°C with the aid of real-time patient 
monitoring and MR imaging and MR thermometry guidance. The treated neuropathic pain syndromes had peripheral 
(5 patients) or central (6 patients) origins and covered all body parts (face, arm, leg, trunk, and hemibody).
Results. Patients experienced mean pain relief of 49% at the 3-month follow-up (9 patients) and 57% at the 
1-year follow-up (8 patients). Mean improvement according to the visual analog scale amounted to 42% at 3 months 
and 41% at 1 year. Six patients experienced immediate and persisting somatosensory improvements. Somatosensory 
and vestibular clinical manifestations were always observed during sonication time because of ultrasound-based neu-
ronal activation and/or initial therapeutic effects. Quantitative electroencephalography (EEG) showed a significant 
reduction in EEG spectral overactivities. Thermal ablation sites showed sharply delineated ellipsoidal thermolesions 
surrounded by short-lived vasogenic edema. Lesion reconstructions (18 lesions in 9 patients) demonstrated targeting 
precision within a millimeter for all 3 coordinates. There was 1 complication, a bleed in the target with ischemia in 
the motor thalamus, which led to the introduction of 2 safety measures, that is, the detection of a potential cavitation 
by a cavitation detector and the maintenance of sonication temperatures below 60°C.
Conclusions. The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neuro-
surgical technique for the treatment of neuropathic pain. The procedure avoids mechanical brain tissue shift and 
eliminates the risk of infection. The possibility of applying sonication thermal spots free from trajectory restrictions 
should allow one to optimize target coverage. The real-time continuous MR imaging and MR thermometry moni-
toring of targeting accuracy and thermal effects are major factors in optimizing precision, safety, and efficacy in an 
outpatient context.
(http://thejns.org/doi/abs/10.3171/2011.10.FOCUS11248)
Key WorDS      •      central lateral thalamotomy      •      neuropathic or neurogenic pain      •       
transcranial magnetic resonance imaging–guided focused ultrasound
Abbreviations used in this paper: CLp = posterior part of the 
thalamic central lateral nucleus; CLT = central lateral thala-
motomy; DT = diffusion tensor; EEG = electroencephalography; 
tcMRgFUS = transcranial magnetic resonance imaging–guided 
focused ultrasound; VAS = visual analog scale; VLp = posterior 
part of the thalamic motor ventral lateral nucleus.
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applying this technique transcranially (that is, without in-
jury to skin and skull) has great potential in the field of 
neurosurgery.16,22
A recent landmark clinical study23 examined the fea-
sibility and initial technical results of tcMRgFUS and 
showed for the first time in 3 patients that it is possible 
to focus the ultrasound beam through the intact skull into 
the brain and to visualize internal heating at the focal 
point and on the brain surface by using MR imaging tem-
perature mapping. These findings constitute a significant 
step forward in establishing an entirely noninvasive alter-
native therapy to surgery for brain disorders.
Based on our long-term clinical experience in func-
tional neurosurgery for neuropathic (or neurogenic) pain 
with radiofrequency stereotactic interventions in the 
medial thalamus,17,19,20 and after preclinical studies with 
phantoms, biological tissues, and ex vivo human head 
preparations, we adapted our interventional procedure to 
perform CLTs in patients suffering from chronic neuro-
pathic pain using the tcMRgFUS technology. The study 
was approved by the ethics committee of Zurich Univer-
sity and the state of Zurich (Kantonale Ethikkommission 
des Kantons Zürich). An initial report about the short-
term results for 9 patients has already been published.26 
The present report provides clinical and neurophysiologi-
cal results over 1 year as well as analyses of the targeting 
precision and the postoperative MR imaging visualiza-
tion of the produced thermolesions.
Methods
Patient Population
Twelve patients with chronic therapy-resistant neuro-
pathic pain were enrolled for tcMRgFUS CLT and provid-
ed their written informed consent. For the sake of safety, a 
thermal spot of only 42°C was placed in the first patient. 
This intervention did not result in a thermolesion and this 
patient was excluded from further analysis. Therapy resis-
tance was established based on the lack of efficacy and/or 
the side effects of antiepileptic and antidepressant drugs. 
Patients were 45–75 years old and suffered from facial pain 
(3 patients), thoracic pain (1 patient), lower-extremity pain 
(3 patients), upper-extremity pain (4 patients), and hemi-
body pain (1 patient), of central (6 patients) or peripheral (5 
patients) origin (Table 1). The causal lesions at the origin of 
the different neuropathic pain syndromes were amputation 
(phantom limb pain, 1 patient), root compression in failed–
back surgery syndrome (1 patient), root compression by 
neurinoma (1 patient), herpes zoster infection (1 patient), 
nerve trauma (1 patient), spinal cord lesion (2 patients), 
putaminal lesion (1 patient), brachial plexus avulsion (2 
patients), and thalamic infarct (1 patient). The duration of 
pain before treatment was between 1.5 and 21 years (mean 
8.5 years). A pre- and postoperative pain assessment was 
performed using a detailed questionnaire, including the 
items of the McGill Pain Questionnaire. The VAS rating 
of pain intensity was noted for the least and worst pain in-
tensities on a scale between 1 and 100. In addition, patients 
provided a global percentage value of postoperative pain 
relief as compared with the preoperative state. In patients 
with chronic therapy-resistant neuropathic pain, a pain re-
lief scale and VAS value comparisons for pain intensity 
reduction after treatment are the most adapted and com-
monly recognized assessment indicators to serve as pri-
mary outcome measures for success. Patients were clini-
cally examined as follows: repetitive assessments during 
the treatment (see below); clinical examination on the eve-
ning of the treatment day and 24 and 48 hours afterward; 
telephone consultation at 1 month after treatment; and full 
reassessment at 3 months and 1 year after treatment.
Prior to treatment, the patients underwent CT scan-
ning (512 × 512 matrix, 1-mm slice thickness) that cov-
ered the entire cranium as well as an MR imaging exami-
nation with T1- and T2-weighted images and DT imag-
TABLE 1: Summary of clinical and treatment data in 11 patients who underwent tcMRgFUS*
Case 
No.
Duration of 
Pain (yrs)
Location of 
Pain Cause of Pain
CLT  
Side
Max Temp at 
Target (°C)
Sensory 
Improvements Activation Effects
1 6 leg root compression (disc herniation) lt/rt 53 + paresthesias in leg
2 8.5 hemibody thalamic infarct lt 51 + vestibular, pain in head
3 2.5 face traumatic trigeminal nerve injury rt† 57 + vestibular, pain in face
4 1.5 face striatal rt 59 − vestibular, nausea, paresthesias in face, 
 pain in face
5 4 face postherpetic neuralgia lt/rt 55 + absent
6 9 arm root compression (neurinoma) lt/rt† 58 + vestibular, vomiting, pain in head
7 17 arm avulsion of brachial plexus lt/rt† 57 − vestibular, pain in head, paresthesias in 
 arm
8 8 leg phantom leg pain rt† 55 − pain in head
9 16 arms & legs paraplegia lt/rt 60 − vestibular, pain in leg
10 7 thorax syringomyelia lt/rt 64 + vestibular, pain in head, nausea
11 21 arm avulsion of brachial plexus lt 64 − vestibular, paresthesias, pain in head
*  The mean duration of pain among the patients was 8.5 years. Neurological deficits occurred in only one patient (Case 11): neglect and dysmetria 
because of bleeding and ischemia. Abbreviation: Temp = temperature ; + = improvement; − = no change.
† Complement to radiofrequency CLT.
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ing. Identical MR imaging series were obtained at 2 days, 
3 months, and 1 year postsonication.
Surgical Procedure
The treatment was performed in a 3-T MR imaging 
system (Signa HDx, GE) using the ExAblate 4000 device 
(InSightec), which features a 30-cm-diameter hemispher-
ical 1024 element phased-array transducer operating at 
650 kHz and held by a mechanical positioner. Magnetic 
resonance imaging was performed using an 8-channel 
torso phased-array coil.
The patient’s scalp was fully and closely shaved, and 
the head was immobilized by fixation in an MR imag-
ing–compatible frame (Radionics; Fig. 1). A circular flex-
ible silicone membrane with a central hole was stretched 
around the patient’s head and sealed to the outer face of 
the transducer to contain the degassed and chilled (15°–
20°C) water that was circulated in the area between the 
head and the transducer. This membrane is tight enough 
to prevent water leakage without preventing blood circu-
lation to the scalp. 
Axial and sagittal T1- and T2-weighted fast spin echo 
images were obtained and coregistered to the previously 
acquired MR and CT images and to the current MR im-
aging/transducer coordinates. These images allowed us 
to calibrate the system and to produce precise stereotactic 
planes for target determination. The target area, the CLp, 
was localized on 3D T1-weighted MR images using the 
stereotactic multiarchitectonic Morel atlas of the human 
thalamus and basal ganglia.27 The coordinates of the tar-
gets were then entered into the planning software of the 
tcMRgFUS system.
Several low-power sonications of 10–20 seconds du-
ration were applied to induce peak temperatures of 39°–
42°C, known to be below the ablation threshold. They 
allowed us to assess the exact position and size of the 
thermal spot and the overall safety profile of the applied 
sonication parameters.15 Several high-power sonications 
were then applied in an iterative process guided by MR 
imaging and MR thermometry, with stepwise increases 
in the acoustic power and energy to finally achieve a peak 
temperature at the target between 51°C and 64°C (Fig. 2). 
The final peak temperature in each treatment is an out-
come of various factors. Thermocoagulation effects on 
tissue can be produced and visualized from 50°C and up, 
with a 100% necrosis considered to arise at 55°–57°C. 
Optimal coverage of the target and the clinical feedback 
from patients both play a role in determining the final 
peak temperatures. These factors explain their range be-
tween 55°C and 64°C for the 9 patients with complete 
lesioning (see Clinical Results). Typically, we applied 
sonications of 10 to 20 seconds in duration with up to a 
maximum acoustic power of 1200 and 800 W, respective-
ly, corresponding to 12,000 J per sonication. The mean 
peak focal temperature achieved in the treatments was 53 
± 3.3°C (range 48°–61°C). 
Patients were fully awake and responsive during all 
stages of the intervention. The only medication admin-
istered before the procedure consisted of lorazepam 2.5 
mg orally. In 2 patients, a subcutaneous opiate injection 
was necessary because of back pain due to a motionless 
supine position on the MR imaging table for an extended 
period of time. During the entire series of sonications, 
patients were examined and questioned repeatedly to en-
sure their neurological integrity and to assess 1) changes 
in pain qualities, extension, and intensity; 2) potential 
somatosensory improvements; 3) the appearance of so-
matosensory, vestibular, and vegetative manifestations 
experienced during the treatment; and 4) the absence of 
any motor or somatosensory deficit.
The CLT was performed unilaterally (contralateral 
to the pain location) in 5 patients and bilaterally in 6 pa-
tients. A bilateral CLT is, in general, necessary, and it is 
as sparing of brain functions as a unilateral one.19 In 4 
patients, the tcMRgFUS treatment complemented a pre-
viously performed radiofrequency treatment. The CLT 
was performed unilaterally for the following reasons: 
complement to radiofrequency treatment (2 patients), ap-
pearance of bleeding (1 patient; see Clinical Results), im-
mediate 100% pain relief after treatment of the first side 
(1 patient), and intolerance of a longer intervention time 
(1 patient).
Target Reconstruction Method
To evaluate the accuracy of tcMRgFUS targeting, the 
3D coordinates of the centers of the sonication lesions, 
outlined on T2-weighted MR images obtained 48 hours 
after sonication, were measured and compared with pre-
surgical stereotactic coordinates of the ablation targets. 
The dorsoventral coordinates were determined by the dis-
tance from the anterior commissure–posterior commis-
sure plane passing through the center of the anterior and 
posterior commissures (on sagittal and/or coronal MR 
imaging); the anteroposterior coordinates, by the distance 
from the posterior commissure (on axial and sagittal MR 
imaging); and the mediolateral coordinates, by the dis-
tance from the thalamoventricular border (on coronal and 
axial MR imaging).
Fig. 1. Photograph of a patient ready for the sonication. The head 
is immobilized in a stereotactic frame. The transducer is held and po-
sitioned by a mechanical positioning system. The silicone membrane 
seals the space between the patient’s head and the transducer, which 
is filled by degassed, cooled, and circulated water.
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Quantitative EEG Procedure
Electroencephalography recording was performed at 
the time of clinical assessment, before entry into the study. 
The clinical states of the patients, reassessed at the time 
of enrollment in the month before treatment, remained 
unchanged, requiring no repetition of EEG recordings. A 
10-minute EEG recording was monitored during alternat-
ing eyes-open and eyes-closed states (2 blocks with eyes 
open and 2 blocks with eyes closed). The EEG activity 
was recorded from a cap with 60 scalp channels (Easycap) 
using a 500-Hz sampling rate, 32-mV input range, and 
0.1- to 250-Hz bandpass filters. The impedance was kept 
below 20 kW. Electrodes were mounted according to 
the 10–20 system plus the following 10–10 system sites: 
FPz, AFz, FCz, CPz, POz, Oz, Iz, F5/6, FC1/2/3/4/5/6, 
FT7/8/9/10, C1/2/5/6, CP1/2/3/4/5/6, TP7/8/9/10, P5/6, 
PO1/2/9/10, OI1/2. Both O1/2 and FP1/2 were placed 2 
cm laterally from the standard positions for more even 
coverage. Note that F1 served as the recording reference 
and F2 was the ground electrode. Two additional elec-
trodes were placed below the outer canthus of each eye to 
measure for electrooculography.
BrainVision Analyzer software (version 1.05, Brain 
Products) served for offline processing of the EEG. Sub-
sequently, electrooculography channels were discarded 
from further analysis. Data were digitally bandpass 
filtered (0.5–70 Hz, 24 dB/oct, and 50-Hz notch) and 
downsampled to 250 Hz. An infomax independent com-
ponent analysis was calculated to remove artifacts related 
to eye movements, eye blinks, and muscle contractions. 
Movement-related artifacts, which may not be suitable 
for independent component analysis correction, were ex-
cluded from the unmixing procedure. Components were 
profiled by their topography, activation time course, and 
spectrogram. After artifact removal, the components were 
first back-projected to the EEG and then transformed to 
the average reference. Segments with remaining arti-
facts were marked and excluded from successive analysis 
(mean length of the EEG was about 4 minutes for each 
resting state condition). Next, the data were parsed into 
2-second epochs. Absolute spectral power was estimated 
for each epoch using fast Fourier transform (Hanning 
window: 10%, zero-padded, resolution 0.5 Hz). The mean 
spectral band power was calculated from 1–48 Hz. Spec-
tral bands were defined as follows: delta (2–4 Hz), theta 
(4–8 Hz), alpha1 (8–13 Hz), and beta (13–30 Hz). (Note 
that the superior spectral band limit is included only in 
the next higher band.) The EEG was analyzed in terms 
of absolute spectral power as well as electrode-wise com-
parisons to preserve topographic information (topoplots). 
For each separate condition, spectral power values were 
averaged across fast Fourier transform epochs and aver-
Fig. 2. Screenshot of the ExAblate 4000 display showing a series of proton resonance frequency MR images (obtained every 
3.7 seconds, upper) and a series of magnitude images (center). Magnification of a proton resonance frequency picture (lower 
left) showing in the center a thermal spot centered in the calculated target display (blue rectangle). Display (lower right) showing 
the applied acoustic energy, sonication duration, acoustic power, target coordinates, thermal scan parameters, and temperature 
curve.
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aged within the above frequency bands. Group means 
were compared using t-statistics (p < 0.05 indicated sig-
nificance).
Results
Clinical Results
In the first 2 patients of this series, the therapeutic le-
sions placed in the CLp, as seen 48 hours after treatment 
on T2-weighted and DT images, were too small to cover it 
in any sufficient manner. The tcMRgFUS treatment could 
thus be considered complete in only 9 of the 11 patients. 
An analysis of global pain relief percentages as reported 
by the patients and of VAS values was performed for these 
9 patients only; results are listed in Table 2. The preopera-
tive mean VAS score was 59.5/100. Significant pain relief 
(mean group value 55%) was already reported during and 
at the end of the procedure. More reliable pain relief per-
centages were collected at 2 days (mean group value 71.1%, 
9 patients), 3 months (mean group value 49.4%, 9 patients), 
and 1 year (mean group value 56.9%, 8 patients) after treat-
ment. The postoperative mean VAS score was 34.3/100 at 
3 months and 35.3/100 at 1 year, representing a 42.3% and 
40.7% postoperative improvement, respectively.
At the 1-year follow-up, among 8 patients, 5 took 
no drugs against pain, but 3 maintained a globally un-
changed regimen. Drug intake is, for many reasons, not 
a good marker of the postoperative evolution of patients 
who have suffered from long-standing, therapy-resistant 
neuropathic pain. On the one hand, some patients may 
have stopped their drug intake before the intervention be-
cause of insufficient or absent efficacy or because of side 
effects. On the other hand, some patients have habituated 
to their drugs for years and are afraid to reduce or stop 
them, making a consequent and predetermined drug re-
duction program practically and ethically impossible.
Six patients experienced significant intraoperative so-
matosensory improvements in and around the pain area, 
which they spontaneously mentioned during the treatment. 
These improvements were confirmed after the intervention 
and remained at the 3-month and 1-year follow-ups.
Patients reported clinical effects during sonication, 
such as pain relief (9 patients), vestibular with or without 
vegetative manifestations (8 patients), paresthesias (4 pa-
tients), or dysesthesias/pain (9 patients). These symptoms 
could already be observed at focal temperatures below 
50°C.
In 1 patient, displacement of the headframe occurred, 
but it was repositioned without negative consequences. In 
the last minutes of the procedure after all planned sonica-
tions had been completed, the last patient in this series 
experienced the acute appearance of right-sided motor 
hemineglect with dysmetria of the arm and leg and dys-
arthria. Magnetic resonance imaging examinations im-
mediately and 48 hours thereafter revealed the presence 
of a bleed 8–10 mm in maximal diameter centered in the 
targeted CLp, as well as ischemic changes in the VLp. 
These were causal for the motor symptoms presented 
by the patient. Subsequent control MR images showed a 
good progressive resorption of the bleeding. Clinically, 
there was a 70%–80% reduction in the motor symptoms 
over the next 24 hours. With time, all dysmetric mani-
festations disappeared except during activation of the 
finer functions of speaking and writing, which at 1 year 
posttreatment remained impeded during demanding and 
stressful personal and professional interactions.
Lesion Coordinate Reconstruction for Assessment of  
Targeting Precision
The sonication lesions were at best visible 48 hours 
after the intervention (Fig. 3 upper) and consisted of a 
mostly hyperintense ellipsoid lesion with a diameter of 
3–4 mm and a length of 4–5 mm. It was surrounded by a 
TABLE 2: Summary of postoperative data in 11 patients who underwent tcMRgFUS*
Pain Relief (%) VAS Score (lowest–highest, mean)
Case No. Acute 2 Days 3 Mos 1 Yr Before Sonication 3 Mos After Sonication 1 Yr After Sonication 1 Yr Postop Drug Intake 
1 100 70 0 lost to FU 70–80 16–79 UN reduced† 
2 30 30 0–30 lost to FU 72–100 40–70 UN unchanged
3 10 100 80 80 52–73, 62.5 5–20, 12.5 9–16, 12.5 stopped
4 70 50 50 95 40–80, 60 0–72, 36 9–36, 22.5 stopped
5 100 80 0 deceased‡ 12–78, 45 0–50, 25 UN UN
6 30 100 90 100 39–62, 50.5 0–11, 5.5 0 stopped
7 30 50 50 40 22–85, 53.5 15–84, 49.5 21–86, 53.5 unchanged
8 100 100 70 50 56–85, 70.5 13–80, 46.5 77 unchanged
9 0 10 0 0 67–90, 78.5 54–89, 71.5 11–84, 47.5 unchanged
10 100 75 90 80 44–91, 67.5 0–14, 7 0–28, 14 stopped
11 75 15 10 25–70, 47.5 30–80, 55 30–80, 55 stopped
overall mean§ 55 71.1 49.4 56.9 59.5 34.3 35.3 UN
*  FU = follow-up; UN = unavailable.
† Includes opiates.
‡  Unrelated medical cause.
§ The mean values for global pain relief and VAS were calculated for Cases 3–11 only.
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fuzzy and irregularly shaped area of perifocal vasogenic 
edema, which completely receded over a month. Lesions 
were significantly smaller at 3 and 12 months after treat-
ment (Fig. 3 center and lower). A detailed neuroradiologi-
cal description of the sonication lesions was previously 
published.26
The median and mean (± standard deviation) of the 
targeting accuracy are given in millimeters in Table 3 for 
the patients in Cases 1–9 and separately for the first and 
second groups treated sequentially. The deviations for the 
first group (5 patients, 9 lesions) are larger in all axes than 
for the second group (4 patients, 9 lesions) treated after 
the implementation of procedural improvements, that is, 
better accuracy in the thermal spot realignment during 
the verification phase at low temperatures, and an optimi-
zation of the determination of the center frequency of the 
MR acquisition for proper thermal imaging projection. 
The increased accuracy between the 2 subgroups was 
most marked in the anteroposterior direction (from 1.17 
± 0.58 to 0.39 ± 0.46 mm). The mean values for the whole 
group are < 1 mm in all axes, but larger in the mediolat-
eral axis than in the other axes.
Localization of the tcMRgFUS lesions in the thala-
mus is illustrated in Fig. 4. Projections of the lesions onto 
horizontal sections of the Morel atlas27 showed the fol-
lowing: of 18 lesions, 7 enclosed most, if not the whole, 
anteroposterior extent of the CLp (targeted in CLT); 5 en-
closed half of it; and 6 enclosed up to one-third. Most par-
tial CLT lesions encroached onto the pulvinar, and only 2 
encroached on the posteriormost part of the mediodorsal 
nucleus. The first series of lesions (Cases 1–5, Subgroup 
1) tended to be more posterior and overlapped less with 
the CLp than the rest of the lesions (Cases 6–9, Subgroup 
2). This result corresponds to the measurements shown in 
Table 3. Note that in the patients in Cases 3, 6, and 7, a 
part of the excentering of the focused ultrasound lesions 
Fig. 3. Magnetic resonance images showing the therapeutic lesions 2 days (2d), 3 months (3M), and 1 year (1Y) after the 
sonication. DTI = diffusion tensor images, isotropic diffusion mode; T1w = T1-weighted images; T2w = T2-weighted images. 
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is related to target adaptations due to previously made 
radiofrequency CLT lesions and not only to suboptimal 
procedural factors.
Quantitative EEG Assessment
The spectral comparison of the 8 patients who un-
derwent a 3- and 12-month follow-up EEG recording re-
vealed 2 major findings. First, spectral power was elevated 
in all frequency bands (delta–beta) before the sonication 
(Fig. 5 upper). Second, frequency band–specific spectral 
power amplitudes were reduced 3 and 12 months after the 
sonication, and thus were approaching the spectral curve 
of healthy volunteers. An electrode-wise comparison of 
frequency band–specific spectral power showed that sev-
eral scalp locations displayed significantly elevated power 
before as compared with 12 months after sonication (Fig. 
5 lower). On the topoplots featured in Fig. 5, black dots in-
dicate the electrodes, which show significantly (p < 0.05, 
t > 2) higher spectral power before as compared with 12 
months after sonication, in delta (2–4 Hz) and theta (4–8 
Hz) bands at frontal, centrotemporal, and parietal elec-
trodes; and in alpha (8–13 Hz) and beta (13–30 Hz) bands 
at centroparietal electrodes.
Discussion
This report on the clinical, neurophysiological, and 
neuroanatomical results of tcMRgFUS CLT for neuro-
pathic pain demonstrates the precision and efficacy of 
this surgical approach and confirms the short-term results 
reported previously.26
The clinical results presented here support our long 
experience with radiofrequency CLT treatment for chron-
ic therapy-resistant neuropathic pain.19,20 The patients in 
this series showed a typical mean group pain relief pro-
file across time, from 71% at 2 days after treatment to 
49% at 3 months and 57% at 1 year after treatment. The 
VAS improvement was similar at 3 months (42%) and at 
1 year (41%). This profile can be explained as follows: 
the immediate reduction of low-frequency overactivity 
using CLT provides the patient with acute relief. How-
ever, complex nonlinear systems, like the thalamocorti-
cal system, display typically protracted dynamics when 
they change from one activity level to another and search 
for a new resting state. This explains why the EEG spec-
tral improvements, in parallel with clinical relief, develop 
over at least 1 year.28,30 After the initial pain relief and as 
the thalamocortical network just begins its retuning (reor-
ganization) toward normal activity, emotional, cognitive, 
and social factors intervene and influence the patient’s 
evolution as he or she revisits specific personal goals put 
aside because of chronic pain and progressively adapts 
to new individual goals and concepts. This endeavor be-
comes less and less demanding as time goes by and the 
thalamocortical network comes closer to normality.
Previous studies28–30 have related the clinical phenom-
enon of chronic neuropathic pain to an increase in low- and 
high-frequency spectral EEG and magnetoencephalogra-
phy activities. This correlation is further supported by the 
evidence of reduced theta overactivity in the EEG record-
ings of patients treated with CLT.28,30 Electroencephalog-
raphy spectral analysis can thus be used as an additional 
tool to diagnose chronic neuropathic pain states and moni-
tor their postoperative evolution. The EEG spectral data 
presented here are fully compatible with these studies and 
demonstrate 1) EEG overactivities in all frequency do-
mains and 2) their reduction, particularly strong in the beta 
range, after the tcMRgFUS treatment. They serve as ad-
ditional evidence in favor of thalamocortical mechanisms 
being at the source of neuropathic pain.
The absence of postoperative clinical deficits, known 
for years about medial thalamotomies, has been con-
firmed for CLT, a medial thalamotomy centered on the 
CLp where an abnormal low-threshold calcium spike 
burst activity was recorded.17 Results in the present study 
confirm the sparing mode of action of CLT, which se-
lectively targets dysfunctional thalamocortical regula-
tors, initiating a resumption of normal thalamocortical 
dynamics while sparing all functions supported by unaf-
fected thalamocortical regulators and executors. The ab-
sence of postoperative kindling of new neuropathic pain 
mechanisms has been shown years after CLT and can 
be related to the selective reduction of the thalamocor-
tical pathophysiology at the source of neuropathic pain 
phenomena.19,20 Six patients experienced immediate and 
significant somatosensory improvements, which persisted 
at the 3-month and 1-year follow-ups. This result corre-
sponds with observations after radiofrequency lesions18 
and can also be related to the reduction of thalamocorti-
cal overactivity by CLT.
Effects during sonication, whether somatosensory, 
vestibular, or vegetative, were observed in all patients. 
They may have 2 origins: 1) an activation of neurons dur-
ing the few seconds before the thermal ablation effect 
and 2) initial manifestations of the resumption of a more 
normal thalamocortical dynamics, as is routinely seen in 
our experience with radiofrequency CLT, thereby indicat-
TABLE 3: Precision of tcMRgFUS targeting*
Total Patients Subgroup 1 Subgroup 2
Parameter Mean ± SD Median Mean ± SD Median Mean ± SD Median
no. of patients 9 5 4
dorsoventral 0.58 ± 0.63 0.5 0.61 ± 0.57 0.5 0.56 ± 0.68 0
anteroposterior 0.78 ± 0.65 1.0 1.17 ± 0.58 1.5 0.39 ± 0.46 0
mediolateral 0.83 ± 0.78 0.5 1.01 ± 0.85 0.7 0.82 ± 0.79 0.5
* Values of dorsoventral, anteroposterior, and mediolateral differences between centers of the sonication lesions and presurgical 
target coordinates are expressed in mm.
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ing appropriate target placement. To monitor safety and 
acquire real-time feedback and information, the pres-
ence of a clinician by the patient’s side throughout the 
treatment phase is required. This practice ensures that 
the sonication effects, including changes in neurological 
parameters, as well as patient safety and comfort during 
the extended period of time in the MR imaging unit are 
closely monitored.
The tcMRgFUS CLT thermolesions as seen on MR 
imaging 2 days after sonication were surrounded by a 
vasogenic edema, which was no longer visible after 1 
month. Visualization of the thermolesion itself receded 
between 1 and 3 months. These observations are indica-
tive of a selective neuronal coagulation with few hemor-
rhagic components, which are often seen with radiofre-
quency thermolesions and correlate with a much longer 
Fig. 4. Localization of tcMRgFUS lesions in the medial thalamus for 9 patients treated for neurogenic pain. The size of the 
lesions (4-mm diameter) corresponds closely with the extent of Zone II seen in the 2-days postoperative axial T2-weighted MR 
image (lower left). The location of the lesion in relation to the CLp is determined by projection of the corresponding atlas maps 
(6.3 [upper] and 8.1 [lower right] mm dorsal to the intercommissural plane) onto the MR image by using the position of the pos-
terior commissure (pc, dotted line) for alignment. The 2 lesions projected on the MR image are the 2 anteriormost lesions in the 
patient in Case 9 (lower right). CL = central lateral; LP = lateral posterior; MDmc = mediodorsal magnocellular division; MDpc = 
mediodorsal parvocellular division; MDpl = mediodorsal paralamellar division; PuM = medial pulvinar; Pv = paraventricular; R = 
reticular thalamic nucleus;  sm = stria medullaris; VLpd = ventral lateral posterior, dorsal division; VLpl = ventral lateral posterior, 
paralamellar division; VLpv = ventral lateral posterior, ventral division; VPLp = ventral posterior lateral, posterior part..
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maintenance of edema. With tcMRgFUS, there is no me-
chanical trauma of the target tissue, and the temperature 
at the center of the hotspot is not as high as with radiofre-
quency ablation. With radiofrequency ablation, the tem-
perature, depending on the electrode geometry, must be 
much higher than 60°C at the electrode tip to achieve the 
necessary heating over the desired target volume. At 48 
hours postsonication, the blood-brain barrier was seen to 
be closed.26 All of these observations are compatible with 
a clean thermolesion displaying a fast healing process and 
speak against the possibility of unexpected deleterious 
long-term tissue phenomena. In this context, the bleeding 
that occurred in our last patient demands an explanation, 
particularly since he presented no increased risk factors 
(he had normal blood pressure and coagulation). A de-
tailed case study was performed to analyze the factors 
that might have facilitated this event. Two factors were 
considered: first, the possibility of the development of a 
cavitation effect, although a detailed analysis provided no 
direct evidence in its favor. Nevertheless, this possibility 
requires the installation of a cavitation detector to detect 
and stop this phenomenon as soon as it appears. Second, a 
temperature-related factor must be considered, supported 
by published evidence32 and confirmed by recent experi-
mental data collected in the context of this case study. 
Accordingly, we recommend maintaining the sonication 
Fig. 5. Upper: Graph showing power spectral curves of the patients before and after surgery with standard deviations of the 
means (vertical bars). Black curve is for controls. Frequency bands are shown in yellow at the bottom of the graph. Lower: 
Topoplots showing electrode-wise comparisons. Black dots indicate the electrodes, which showed significantly higher spectral 
power before surgery as compared with 12 months after surgery.
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temperatures below 60°C. Note that the bleeding itself, 
centered in the adequately targeted CLp, did not produce 
deficits. It is the ischemia, extending anteriorly and later-
ally into the VLp, that caused the typical motor symptom-
atology. We hypothesize a blood-induced vasospasm in 
the VLp as a causal link between the 2 events.
Our target reconstructions demonstrate precision 
within a millimeter for all 3 target coordinates. The clas-
sic stereotactic techniques involving penetration of an 
electrode into the brain cannot, despite adequate tech-
nological accuracy, reach such final precision because of 
the unforeseeable mechanical shift of brain tissue by the 
electrode.1 In addition, the tcMRgFUS CLT should allow 
for optimal target volume coverage thanks to the absence 
of electrode trajectory restrictions. Such optimization 
should develop with increased procedural experience and 
further technological developments, both decreasing the 
time devoted to optimal target coverage during treatment. 
This should correlate with higher long-term pain relief 
scores as compared with our previous results with CLT.19 
The patient group in the present study is too small to be 
conclusive on this question, and further long-term studies 
on larger patient groups will have to verify whether this is 
indeed the case. Sonication also proved to be particularly 
helpful for 4 patients who had previously been treated 
with radiofrequency CLT, facilitating the complemen-
tary treatment by avoiding potential shifts of penetrations 
through gliotic tissue.
Conclusions
Results of the current study highlight the precision 
and efficiency of tcMRgFUS for treating chronic neuro-
pathic pain. The noninvasiveness of the procedure and 
specifically the continuous MR imaging and MR ther-
mometry monitoring of the intervention represent major 
factors toward an optimization of safety conditions. This 
radiation-free technology can be applied to other func-
tional brain disorders as well as to numerous other neu-
rosurgical indications and is an important option because 
of the elimination of brain tissue shift or trauma during 
therapy. Besides, tcMRgFUS has a probably reduced 
bleeding risk, no risk of intracranial infection, and is not 
limited in target coverage by trajectory constraints.
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